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Abstract 
Cancer is a leading cause of death in Small Island Developing States (SIDS), and is forecast to increase 
substantially over the coming years. Governments, regional agencies, and health services of SIDS 
face daunting challenges - including small and vulnerable economies, unequal distribution of 
resources, weak or fragmented health services, small population sizes making sustainable workforce 
and service development problematic, and specialised cancer services unavailable to many. 
Deliberate action is required to prevent massive human and economic costs relating to cancer. This 
paper highlights challenges and opportunities for SIDS, and identifies ways in which the international 
community can support efforts to improve cancer control in these settings. Our recommendations 
focus on funding and investment opportunities for cancer-related health system strengthening, 
sharing of technical assistance for research, surveillance, workforce and service development, and 
supporting SIDS with policies changes to reduce consumption of commodities that increase cancer 
risk. 
Introduction 
What are Small Island Developing States?  
In 1992, the United Nations (UN) formally recognised a group of small island developing countries 
that faced ‘specific social, economic and environmental vulnerabilities’.1 These countries vary 
substantially in their development, size, cultures, languages, and history, but they also share certain 
features – including geographical isolation, fragile economies, ageing populations, and environments 
affected by global warming, making them vulnerable to natural disasters. Most have small 
populations and limited economies of scale, and are therefore heavily reliant on resources from 
larger neighbouring countries despite the high cost of transport, infrastructure, and 
communications.1 Another common feature of these countries – closely linked with these 
characteristics – is their often under-developed health systems including limited workforce resource.   
Whilst there are no specific criteria for being classed as a Small Island Developing State (SIDS), more 
than 50 countries (not all of them islands) are currently recognised as such (Table 12). SIDS are 
located across three broad geographical areas: the Pacific; the Caribbean; and the Atlantic, Indian 
Ocean, Mediterranean, and South China Seas (AIMS). They are represented by a number of regional 
organisations, including the Caribbean Community,3 the Pacific Community,4 the Indian Ocean 
Commission,5 and the Alliance of Small Island States (AOSIS)6 which acts as a regional integration 
forum to address common challenges of economic, social, and sustainable human development.6 
Some regional organisations deal specifically with health issues: for example, the Caribbean Public 
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Health Agency (CARPHA) 7 has a focus on communicable diseases, disaster management, and the 
surveillance and prevention of non-communicable diseases (NCDs), while the Pan American Health 
Organization (PAHO)8 operates as the regional office of the Americas for the World Health 
Organization (WHO), and the health agency of the Organisation of American States.  
State of cancer control in SIDS  
The unique and heterogeneous nature of SIDS is often overlooked within global, or low and middle-
income country (LMIC) cancer control agendas. Their small size is associated with capacity issues in 
key aspects of cancer prevention and control, from functioning registries to access to radiotherapy. 
This paper aims to highlight specific challenges and opportunities for SIDS, and to identify ways in 
which the international community can support governments, academic institutions, and civil society 
efforts to improve cancer control in these settings. 
Pacific and Caribbean regions 
The first four papers in this series outlined the state of cancer control in the two main SIDS regions, 
the Pacific and Caribbean. Both regions share characteristics common to (most) SIDS – that is, small, 
geographically dispersed populations with limited financial and healthcare resources. Both struggle 
with adequate human resources for health and the impacts of global warming and natural disasters, 
with seven of the fifteen countries at highest risk of such impacts (Vanuatu, Tonga, Solomon Islands, 
Papua New Guinea, Fiji, Costa Rica and Kiribati) located in one of these two regions.9 Both Pacific 
and Caribbean countries experience policy and intervention gaps along the cancer control 
continuum, although the scope and likely solutions to these problems differ. On the upside, the 
relatively small populations and strong cohesion across the two regions may offer opportunities for 
flexibility and innovation in collective approaches to cancer control.10 On the international stage, the 
SIDS have frequently formed an effective lobby  in advocating for greater attention to climate 
change and its impacts on their economies and environments.11  
There is substantial heterogeneity both within and between these two regions. The Caribbean 
contains considerably more wealth, albeit distributed very unevenly.12 Private health care plays a 
substantially bigger role in specialised cancer care, with private public partnerships representing a 
prominent approach to delivering such care (ref paper 3, Spence et al). In the Pacific, more limited 
cancer care is available on a highly centralised basis, due to very small populations and vast 
geographic distances. In the Caribbean, treatment requiring substantial capital or infrastructure 
(such as radiotherapy) is available in some countries, but frequently with challenges in maintaining 
quality, and accessible only to those able to pay. In the Pacific, specialist facilities are often absent 
altogether – meaning many treatments are available only to those who can afford to seek them in 
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neighbouring countries. Thus, both regions experience marked inequalities in access to cancer care, 
though the underlying mechanisms are somewhat different. 
Textbox 1: Role of the Commonwealth in cancer control in SIDS 
Many countries in both the Caribbean and Pacific belong to the Commonwealth – which provides a 
sense of connection and community in a shifting global landscape. Many island populations in the 
Caribbean identify more closely with the Commonwealth than with Latin America; while the Pacific 
includes eleven Commonwealth member states, all discrete island nations except Papua New 
Guinea. The Commonwealth’s networks and convening power mean it is well-placed to contribute to 
cancer control efforts in these regions. It can provide representation at international fora (such as 
the UN), high-level advocacy on issues relevant to member countries, and has a track record for 
effecting change in areas of common concern such as climate change and antimicrobial resistance.  
Consistent with the UN’s third Sustainable Development Goal (SDG) and Political Declaration on 
NCDs, the Commonwealth has recognised NCDs as “a human development challenge which needs to 
be tackled urgently”13 and has expressed commitment to raising awareness, mobilizing resources, 
and ensuring accessibility to the necessary prevention and treatment services.14-16 In relation to 
cancer, the Commonwealth has led on some relevant initiatives. For example, the ‘Cervical Cancer in 
the Commonwealth: Collective Action’ programme has analysed the burden of cervical cancer in 
LMICs of the Commonwealth.17  
Much more needs to be done, however, and this series of papers should catalyse further 
Commonwealth action on cancer. While still lacking a comprehensive cancer strategy, new initiatives 
such as the Commonwealth Innovation Hub have the potential to enhance and co-ordinate cancer 
control efforts among member states.18 There have been calls to establish a Commonwealth Cancer 
Fund to “build up capacity in cancer control in the smaller and less economically advantaged 
Member States through skills training and multilateral aid.”19 In relation to the Caribbean and Pacific 
Islands, there is interest in Commonwealth support for Human Papilloma Virus (HPV) vaccination 
and cervical screening in its member states, and for improvements in the early detection, diagnosis, 
and treatment of childhood cancers.20  
 
AIMS SIDS 
Outside the Pacific and Caribbean regions, there are other UN-recognised SIDS collectively referred 
to as AIMS SIDS (table 221-25). In addition, there are other island countries and territories not 
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explicitly mentioned in this paper which share similar experiences and challenges, and which 
similarly need support to develop more effective cancer control systems.  
There is marked variation between the AIMS SIDS (table 2). At one end of the spectrum, Singapore 
and Bahrain are high-income countries (HICs) with national population-based cancer registries, 
operational cancer and NCD plans, and comprehensive cancer services providing specialised surgery, 
chemotherapy, radiotherapy, and palliative care. Conversely, advances in cancer surveillance, 
screening and prevention, diagnosis, and care have been limited in almost all other AIMS SIDS. For 
instance, the Comoros and Guinea-Bissau are among the poorest countries in the world and struggle 
to meet their populations’ basic needs: sanitation, nutrition, transportation, and basic healthcare. 
Life expectancy remains low, and fragile health systems are burdened by multiple competing 
priorities including infectious diseases. Long periods of civil unrest in Guinea-Bissau have resulted in 
debilitated health systems, significant workforce shortages, and delayed progress in health 
infrastructure development. The double burden of lifestyle and infection related cancers is evident 
in many of these SIDS, with GLOBOCAN 2018 estimates showing the most common cancers are 
breast, cervical, and colorectum in women, and colorectum, prostate, liver, and lung in men (table 
326).  
Outside of Bahrain and Singapore, cancer surveillance and prevention programmes are very limited. 
Mauritius and Seychelles are the only other AIMS countries (besides Bahrain and Singapore) to have 
population-based cancer registries, although pockets of cancer registration activity occur elsewhere 
(for example, Cape Verde has a hospital-based cancer registry). Despite the high burden of 
preventable cancers, none of these countries have established national screening programmes for 
cervical or breast cancers, and only two (Mauritius and Cape Verde) have operational standalone 
cancer plans in place. More positively, uptake of hepatitis B immunisation has been successful (>90% 
coverage) in most of these SIDS. A growing number of SIDS are incorporating Human Papilloma Virus 
(HPV) vaccination into their national schedules, with the Maldives recently approving HPV for roll-
out to 9-15 year old girls.27 As with other SIDS, many cancer prevention and educational campaigns 
in these countries are spearheaded by non-governmental organisations (NGOs) or patient groups.28  
Diagnostic and treatment services are variable in all AIMS SIDS besides Bahrain and Singapore. The 
availability of histology and cytopathology services is very limited, and none have positron emission 
tomography (PET) scan capability. Chemotherapy is available in four countries, and Mauritius is the 
only AIMS SIDS (besides Bahrain and Singapore) with radiotherapy capabilities. Like other small 
islands globally, some AIMS SIDS have established pathways for accessing diagnostic and treatment 
services off-island by sending selected specimens or patients to neighbouring countries and/or 
7 
 
receiving visiting specialist services.28 For instance, Cape Verdeans may be transferred to Portugal for 
radiotherapy and other oncological treatment not available in-country; patients from the Seychelles 
may seek comprehensive care in Sri Lanka, Reunion, or India; and Mauritius has an overseas 
treatment scheme for brain tumours.  
Like the Pacific and Caribbean SIDS, innovations in cancer control and care are emerging in these 
SIDS. For example, the Comoros has partnered with the Felix Guyon University Hospital, Reunion, to 
provide a route for cancer diagnosis by sending tissue samples offshore, and with Mauritius and 
Madagascar to improve chemotherapy delivery on Comoros. Oncologists from the Portuguese-
speaking SIDS (Cape Verde, São Tomé and Príncipe, and Guinea-Bissau) are collaborating to advance 
cancer control efforts via strategies such as improving access to cancer care, increasing cervical 
cancer screening and HPV vaccination, and developing educational, training and research pathways 
through their connection as PALOP (Países Africanos de Língua Oficial Portuguesa) countries.28  
Textbox 2: SIDS, the sustainable development goals and universal health coverage 
The sustainable development goals (SDGs) include target 3.4, to reduce by a third premature 
mortality from NCDs through prevention and treatment. However, the potential role of NCD control 
in achieving SDGs (or not) extends well beyond this specific target.29 The special case of SIDS in 
achieving and prioritising sustainable development was detailed in the SIDS accelerated modalities 
of action (SAMOA) pathway, which was developed at the third International Conference of SIDS in 
2013, and resulted in a resolution adopted by the general Assembly of the U.N. in 2014.30 The 
SAMOA pathway acknowledges the significance of health as foundational across SDGs, identifies the 
critical importance of international cooperation and partnerships in achieving them, and the central 
role of multisectoral strategies for both preventing and managing NCDs. This includes the 
strengthening of health systems and acceleration of universal health coverage implementation. SIDS 
vary substantially in terms of the extent to which they need to  address the three inter-related 
elements of coverage as defined by the WHO31; ensuring financial protection by reducing reliance on 
out-of-pocket payments for patients, expanding the services covered ensuring that those selected 
are high priority, cost-effective and high quality services, and increasing the population covered. For 
example, in several Caribbean countries, out-of-pocket payments of cancer care remain high, while 
in most Pacific SIDS, a key issue is the relatively narrow scope of cancer treatment services available. 
Responding to these challenges, and the burden of cancer generally, requires integrated and 
coordinated policies and strategies within SIDS, with international partnerships and support to 
prevent and treat cancer. Progress in cancer control is absolutely integral to accelerating progress 
towards achieving SDGs within the challenging context facing SIDS.  
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Common threads leading to recommendations 
Many reports have summarised evidence on cancer control requirements within LMICs and 
developed recommendations for strengthening existing systems.32-40 These have relevance for SIDS, 
although the unique circumstances of remote island states create distinctive challenges for cancer 
control. While acknowledging the diversity of this heterogeneous group, we highlight below the 
common themes in SIDS’ experience of addressing the burden of cancer in their populations and 
implications for policy. 
Monetary and Fiscal Policy for Cancer Control in SIDS 
The economic case for investing in cancer control - from specific modalities such as radiotherapy and 
surgery through to population-based measures such as women’s health initiatives, HPV vaccination 
and bowel cancer screening - is equally applicable to SIDS.34,36,37 Good outcomes in cancer control 
are also highly sensitive to equity-centred fiscal policy, requiring significant public health 
expenditure (about 5-6% of GDP and at least $100USD per capita) and effective governance.41 
Where private investment and provision for cancer is present, it should be a minority partner that is 
well integrated into public care. This runs counter to the World Bank’s historic approach to SIDS, 
which focuses on private sector-led growth in health and cancer care that necessarily requires 
stable, progressive economies. Yet SIDS have some of the most vulnerable economies in the world, 
facing serious constraints due to demographic and geographic characteristics. It is clear that 
investment in public health care is critical to maintain economic growth, even if this comes with 
larger budget deficits.42 Cancer is a major cause of lost productivity due to premature mortality and 
morbidity, and effective public investment in cancer prevention and early diagnosis (including 
tobacco control, vaccination, and screening) will reduce the economic burden of cancer in 
transitioning economies.43 Unfortunately, some SIDS are currently pursuing unaffordable programs 
focused on costly treatment of conditions affecting a small proportion of the population.44 The 
failure to invest and tackle the causes of cancer – such as tobacco consumption - seriously 
undermines the economic sustainability of many SIDS (see section below on NCD prevention).  
Growth in population-level drivers of cancer (such as tobacco and obesity) are expanding the burden 
of cancer in SIDS beyond what can be addressed via current fiscal policy. Given infection-related 
cancers are still high, the emergence of a “double disease burden” creates substantial economic 
challenges in supplying even a basic package of cancer care, which may be beyond what individual 
SIDS can achieve. Joint country models need to be examined, where geographically co-located SIDS 
create a single ‘system’ (discussed further below). It may be feasible and cost effective to provide 
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only basic community services in those SIDS with good access to specialist facilities in neighbouring 
HICs.45 There is a need for more empirical evidence on the cost-effectiveness of such models and 
pathways. Ad hoc support though official development assistance (ODA) funding is not a long term 
solution;46 rather, major ODA programs need to be created that specifically address cancer control in 
SIDS via public health and prevention initiatives. More widely, new tariffs and excise duties on 
unhealthy commodities need to be built into bilateral trade agreements in order to reduce the 
drivers of cancer and generate revenue for prevention and control activities, while still retaining 
SIDS’ access to global markets which are crucial to sustainable economic growth.47  
Regionalisation of cancer planning and services 
A common practice among island nations is regional collaboration with external partners to facilitate 
the management of health programmes, including (in recent years) cancer control programmes. 
Such programmes typically involve an interweaving of regionalization (in which an external agency 
works in collaboration with a particular geographical region) and regionalism (in which individual 
countries within a geographical region come together for a common specific purpose, supported by 
bodies that express their collective identity and shape collective action). 
The WHO often works in collaboration with a particular geographical ‘region’ in management of 
specific health care needs. In the Pacific, for example, this regionalisation has allowed prompt and 
affordable access by smaller nations to technical expertise for programme development. The Cancer 
Council of the Pacific Islands (CCPI), which operates in U.S.-affiliated Pacific islands (USAPIs), 
provides a well-established example of how locally-controlled regionalism can be initiated, with the 
CCPI using the University of Hawai’i as a gateway to funding and support, leading to a regionally-
recognized cancer control plan and registry.48,49 A further example of regionalisation is provided by 
the Pacific Regional Cancer Control Partnership (PRCP), which includes international partner 
agencies.49 Managing cancer control in SIDS at a regional level means that collaborating SIDS can 
share resources and gain greater leverage for funding requests and global advocacy.  
A regionalisation strategy for cancer prevention and control may be an effective way forward for 
SIDS in other regions. Regional efforts are most likely to be effective where they link countries that 
share a common language, historical and/or political affiliations in addressing a common need or 
goal such as national comprehensive cancer planning, or the development of regulation of medicines 
and health technologies.50,51 Opportunities for such linkages may be found in existing government-
led initiatives (e.g. the Caribbean Cooperation in Health and the Ministers of Health Caucuses of 
both the Pacific and Caribbean regions), in national and international cancer societies, in regional 
and local networks of NGOs (e.g. the Caribbean Cooperation in Health), in academia, or via 
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international organisations such as the International Agency for Research on Cancer (IARC) which 
has established cancer registry hubs in many regions. 
The motivation for specific SIDS to be involved in regionalization or regionalism efforts will vary, 
depending on individual country resources, needs, and geopolitical support. High level regionalism 
requires support from health leaders in the relevant countries in order to identify the preferences, 
scope and nature of the collaborations.  In order for such approaches to be effective, there needs to 
be sufficient political will (both across and within partner countries) to sustain collective action and 
outcome; mutually agreed institutional ‘housing’ and governance structures; and ongoing review 
processes. Equally important is that leadership and decision-making occur collaboratively, and 
reflect the needs and priorities of the constituent countries.   Regional agencies, academic 
organisations, and non-Governmental Organisations are critical to provide resource for planning and 
working to deliver key actions according to agreed regional approaches.  
Implementation policy that supports NCD control more generally  
SIDS face particular challenges in developing coherent and effective approaches for cancer 
prevention. Key drivers of the growing cancer burden in these states include their dependence on 
and vulnerability to imported goods – some of which are health-promoting, but many of which are 
health-damaging.52,53 In line with a broader development agenda, many SIDS have been encouraged 
to follow a programme of trade liberalisation as a means of attracting foreign investment and 
reducing the cost of imported goods.52 The removal of trade barriers has been associated with 
increased consumption of tobacco, alcohol, and highly processed food and drinks, which collectively 
account for around 30% all cancers.54,55 
 
Cancer prevention thus requires measures to reduce population consumption of unhealthy 
commodities, with the most effective strategies involving taxation, tariffs, and restrictions on 
marketing.33 While SIDS experience particular challenges in balancing health and trade goals, there 
are some promising examples of successful efforts to protect island populations from unhealthy 
commodities.56 The Cook Islands, Palau, and Tonga have all introduced tobacco taxes close to the 
WHO target (70% of the sale price)57; several Pacific and Caribbean countries have imposed 
significant taxes on alcohol and sweetened beverages;58-60 and some Pacific countries have banned 
importation of specific unhealthy items such Tokelau’s ban on the importation of sweetened fizzy 
drinks.52 While there is ongoing work across the Caribbean to address these issues, there is scope to 
do more, however, particularly in relation to tobacco control in the Caribbean,61 where several SIDS 
lack effective advertising bans and have tax levels below 25%.57,62 Raising taxes on tobacco, alcohol, 
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and sugar-sweetened beverages has the potential to increase government revenue while also 
reducing the burden of NCDs.33 
 
Developing cancer treatment services in SIDS  
 
Workforce 
Efforts to strengthen their health workforces will be key to enhancing cancer control within SIDS. As 
with many LMICs, SIDS struggle with limited workforce training, retention, professional support, and 
development opportunities, exacerbated by a lack of infractructure and equipment; movement of 
resources from public to private settings; and migration of specialised healthcare workers to HICs. In 
addition, the small population size of many SIDS limits the feasibility of specialised services, including 
cancer treatment centres, with models from HICs or even larger LMICs not applicable in these 
settings.63 For example, a recent analysis noted than ocology stafffing is insufficient to meet the 
current demands of the poluation.64 While the need for workforce development is recognised within 
the SDGs (target 3c), 65 SIDS are competing with other countries in a context of marked scarcity, with 
the global shortage of health workers estimated to reach 15 million by 2030.66 
 
The challenges facing SIDS in developing a cancer workforce are daunting. Given their small and 
dispersed populations, highly specialised services are neither feasible nor affordable. For many SIDS, 
treating patients offshore is the only option – but health-related travel is expensive and complex and 
results in poor continuity of care, high out-of-pocket costs for patients and their families, and limited 
incentive to improve local services.67 
 
Despite these challenges, there are significant opportunities for strengthening the cancer control 
workforce within SIDS. Health workforce development is a priority in both the Pacific and Caribbean 
regions, with efforts underway to improve workforce planning, education and training, as well as its 
regulation and monitoring.68,69 Regional or subregional approaches can enhance the efficiency and 
the effectiveness of health workforce planning, and offer opportunities to share successful 
approaches. In the Pacific, for example, health workforce development has been a major agenda 
item in recent meetings of the Pacific Health Ministers;70 and there are a number of collaborative 
groups and programmes that work to enhance training and continuing professional development, 
including the Pacific Regional Clinical Services and Workforce Improvement Program.70 Significant 
challenges persist, however, including a lack of specific attention to cancer prevention and 
treatment in workforce development.70 Similarly, in the Caribbean, several adhoc efforts for training 
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and building cancer workforce capacity have taken place, however a systematic process for cancer 
control workforce planning, development, and continuing education is still needed in the region.   
 
Role of traditional healers 
In most SIDS, traditional healers play an important role, but there is almost no research on either 
their impact on health or their potential to provide links between traditional and conventional 
medicine. Many people in SIDS will visit their traditional healer before seeking conventional medical 
care, and will continue to do so during treatments, and at the end of life. Traditional healers work 
with patients and families within their own communities. They use concepts and language that are 
familiar and congruent with understandings of health and disease within those communities.  
Engaging with these healers, and encouraging a complementary approach with conventional 
medicine, is likely to pay dividends. For example, more timely diagnosis and access to treatment may 
be achieved by training healers to recognise common cancer symptoms and refer patients to 
conventional services; while the involvement of traditional healers in conventional cancer care may 
improve its accessibility and provide patients with ongoing spiritual and mental support. Such 
innovative approaches would require identifying traditional healers who are prepared to work in 
partnership with conventional medicine, ongoing relationship building, consideration of the need for 
structural changes in the clinical setting to provide space for traditional healers, consideration of 
training needs of those healers, and attitudinal shifts for clinicians.71 
 
Ensuring a reliable and affordable supply chain 
A robust supply chain of essential medicines and supplies is essential to deliver effective and timely 
cancer diagnosis and treatment. Individually SIDS have little purchasing power, and little prospect 
for economies of scale. Centralised approaches to procurement and supply have been found to 
generally both reduce costs and improve supply including across countries.51,72 One of the most 
successful examples is the Organisation of Eastern Caribbean States Pharmaceutical Procurement 
scheme (OECS-PPS) which was established in 1986.73 The OECS-PPS operates as a monopsony 
purchaser of pharmaceuticals and medical supplies to nine small island countries. This approach has 
resulted in increased bargaining power and improved economies of scale, resulting in substantial 
reductions in drug prices, as well as improved supply chain and quality assurance processes, 
reductions in operational costs and better-informed selection and standardisation of 
pharmaceuticals.74 The key success factors have previously been described in detail.73 PAHO’s 
Strategic Fund for Essential Medicines also offers a pooled procurement mechanism for medication 
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for participating countries in the Americas, including the Caribbean, resulting in improved pricing 
and purchasing, although it remains underutilised for cancer medications.75 
 
Innovative approaches to delivering cancer care for SIDS 
Innovative approaches to delivering cancer care are necessary in the context of many SIDS, where 
highly specialised models transplanted from HICs are unlikely to be useful. There is increasing 
recognition of the important role of primary care in cancer prevention, diagnosis, treatment, 
survivorship, and end of life care.39 Arguably, this is particularly critical in the context of SIDS where 
secondary care services may be limited or even absent. Where it is available, specialised cancer care 
is typically limited to regional centres, and in many cases patients will have to leave the region 
altogether to access such care. This highlights the importance of enhancing what cancer care can be 
provided within specific islands. Nurses and allied health professionals are a valuable resource, 
potentially providing a range of cancer-related care – including prevention activites (such as smoking 
cessation advice), screening, treatment, palliative and survivorship care.76,77  Supportive and 
palliative oncological care is provided by generalist medical practitioners in some SIDS; this could 
potentially be extended with input from colleagues in HICs. Such partnership arrangements exist for 
paediatric cancer in both the Pacific and Caribbean regions, and have resulted in subsantially 
improved outcomes for affected children (ref papers 2, Ekeroma et al and 4, Spence et al). These 
collaborations typically involve country-specific policies and procedures for communication and 
referral, as well as regular virtual and face-to-face meetings between clinicians based in SIDS with 
those based in HICs. A number of factors must be in place for such models to be effective and 
sustainable, including a commitment from the government and relevant healthcare workers that 
providing basic oncological services is a priority; training and professional support opportunities; and 
access to relevant infrastructure, policies and procedures, and equipment. 
 
Online professional development, consultation, and mentoring programmes offer particular 
potential for SIDS, and are already supporting care in some contexts. For example, the Pacific Open 
Learning Health Net (POLHN) was established by the WHO and Pacific Ministers of Health in 2003, 
and provides accredited, freely accessible learning opportunities for health workers in the region on 
a broad range of topics.78 Currently, the majority of these are not cancer-related, but such a 
platform would be ideally placed to increase training opportunities for cancer care workers.  
 
Other technological solutions to support local healthcare workers include the use of telemedicine 
and point of care technologies. These collectively have great potential for improving cancer 
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detection, diagnosis and treatment, particularly in settings with limited infrastructure, as is the case 
in many SIDS.79  Telemedicine can particularly support local clinicians  with pathological and 
radiological diagnosis. 40  Point of care technologies have a range of uses, including HPV screen and 
treat programmes that have been positively evaluated in SIDS settings.79-81 Tele-mentoring 
programmes such as the Extension for Community Healthcare Outcomes (ECHO) program support 
local clinicians to provide care of complex diseases with support and mentoring from specialists. 82 
The ECHO program runs regular virtual ‘clinics’ held using commonly available videoconferencing 
technology, where local clinicians can present and discuss cases, and specialists, based in central 
hubs, can provide expert knowledge and experience. ECHO is increasingly being used across the 
cancer control continuum in LMICs settings - including in the Caribbean - to support comprehensive 
cancer plan development.83 This approach could be expanded improve access to specialist cancer 
care in other SIDS. 
 
Both telemedicine and tele-mentoring approaches require consistent, reliable, and affordable 
internet access, which may be problematic in some SIDS. Other potential barriers include high set-up 
costs, particularly for telepathology (which requires high-quality imaging), regulatory and legal 
requirements, and quality assurance processes for experts (such as pathologists) based in other 
countries.40 However, the clear advantage of telemedicine is that health services in small countries 
may be able to access expertise in contexts where it is not feasible for them to maintain highly 
specialised services in-country. 
 
International referrals  
For many SIDS, it is not feasible to deliver comprehensive cancer treatment in-country – meaning 
patients must sometimes travel internationally for treatment. Travelling to receive treatment out-of-
country can be complex and expensive, particularly in the context of time-sensitive care. Even where 
treatment costs are covered by Government, costs to patients for travel and accommodation can be 
catastrophic, or entirely out-of-reach for many patients. In addition, in order to ensure timely 
treatment, processes to facilitate treatment offshore must be efficient and streamlined. Given 
scarce resources, and high demand, this is not always the case. There is very little empirical research 
on the impact and costs of international referrals, nor on optimal models of such referrals. Critical 
questions remain unanswered on nearly every aspect of these referrals including the psychosocial, 
economic, and health impacts of international referrals on patients and their families, the impact of 
costs of these referrals on the referring country including their effect on the development of local 
services, identification of factors that make such referrals more or less successful, and the potential 
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role of the international community in assisting with funding or coordinating such referrals. Research 
in this area is urgently required. 
Building surveillance and research infrastructure  
Underpinning all the work required to strengthen cancer care within SIDS is the necessity for data 
systems to support cancer surveillance and inform locally-relevant priorities and policies. Evidently 
effective surveillance programmes including risk factor surveys, vital registration systems, and 
population-based cancer registries (PBCR), as well as clinical information systems are all esential to 
plan and evaluate interventions tailored to the local scale and profile of cancer. Cancer registration 
has a long history in SIDS, but has been historically challenged by limited health care infrastructure, 
including pathologist services. As a means to improve data quality and PBCR coverage in the 
Caribbean and Pacific Island regions, the IARC, with several partner organisations, have developed 
IARC Regional Hubs, as part of the Global Initiative for Cancer Registry Development 
(http://gicr.iarc.fr). The Regional Hubs provide the necessary technical guidance, training, advocacy, 
and research capacity-building to ensure the sustainable development of high-quality PBCR in these 
regions. A sustainable expansion of high-quality registries in the SIDS is thus feasible and underway, 
but given small population sizes in many states, regional approaches equally apply to surveillance, 
including PBCR. As with other programmes of local data collection, funding remains problematic for 
this initiative, despite the relatively small amounts required.   
 
Local evidence to inform policy design and programme delivery in cancer control and prevention is 
badly needed in the SIDS. While there are many examples of productive partnerships between HICs 
and SIDS, research systems are often under-developed or non-existent in many SIDS.84-86 The 
ongoing building of research capacity and infrastructure is essential for progressing SIDS’ cancer 
control efforts as the health and cost burdens grow. This will be facilitated by continuing 
development of genuine collaborations between SIDS and HICs that address local research priorities, 
strengthen research infrastructure, and create impact by interpreting and implementing research 
findings in a way that is appropriate to local context.87  
 
Start with the things that are likely to be easier, cheaper and quicker to implement with high impact  
In seeking to manage cancer, SIDS face difficulties common to many LMICs while also experiencing 
some unique challenges. Cancer control in these settings is often seen as prohibitively expensive, 
and a lack of strategic prioritisation leads to missed opportunities for its inclusion in broader health 
systems strengthening agendas.88 Yet much can be done to reduce suffering and premature death 
from cancer, even in resource-constrained settings.  
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The WHO recommends a stepwise approach to building a national cancer programme.89 Alongside 
this, it encourages the prioritisation of effective tobacco control policies in order to reduce the most 
significant risk factor for cancer. As noted above, taxes on tobacco can also provide much-needed 
revenue to support health systems development.  
Interventions based in primary and community settings offer particular promise in resource-poor 
settings. Such programmes can be effective even in the absence of specialist services or 
infrastructure, and offer alignment with broader development and universal health care goals. 
Palliative care is explicitly recognised under the human right to health.38 In LMICs, and even in SIDS 
classified as HICs, palliative care is an often neglected aspect of cancer care. This is particularly 
significant given that these countries are dealing with a high percentage of cancer patients with 
advanced disease for whom palliative care and pain relief are often the only option. Palliative care 
can be substantially enhanced via existing primary and community-based services. While many 
aspects of cancer care require costly and/or sophisticated treatment modalities, palliative care can 
be strengthened at relatively low cost by improving access, understanding, and coordination of care 
within existing systems.38 Key priorities include efforts to increase the accessibility of essential 
medicines including immediate release and injectable morphine, simple equipment, and 
competency based human resources.38 The essential package (of palliative care and pain relief 
health services) has been shown to be inexpensive and is applicable in countries at all stages of 
palliative care development.38 Regional organisations such as the Caribbean Palliative Care 
Association play an important role in raising awareness and coordinating provision of palliative care, 
which is often misunderstood and/or neglected in existing health systems.90  
 
Prevention of cervical cancer – a leading cause of cancer death in many SIDS – offers significant 
potential gains. HPV vaccination and cervical screening are cost-effective interventions recently 
highlighted as priorities by the Director General of WHO.91 The international community can help 
SIDS strengthen their cervical cancer prevention efforts by supporting regional purchases of HPV 
vaccines and assisting countries in designing and implementing screening programmes tailored to 
their local context. For example, Papua New Guinea has introduced point-of-care screening using 
HPV-DNA testing; this offers a promising approach in SIDS countries where cytology is not available 
and approaches based on VIA (visualisation of the cervix after acetic acid) have had poor results.81,92   
The role of the global cancer control community 
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Global efforts in cancer control have tended to focus on issues facing LMICs but not the particular 
vulnerabilities of SIDS. Smaller populations with inherent capacity issues, geographic isolation and 
environments increasingly affected by the consequences of global warning result in unique 
challenges. While, the sovereignty of states is paramount in the development of health policy, the 
global community has an important role in facilitating SIDS’ own efforts to strengthen their cancer 
prevention and control systems. Key members of the global community include international 
organisations (such as WHO and its regional offices in the Americans and the Western Pacific), global 
alliances and networks (such as the Commonwealth, IARC, the European Union-African Caribbean 
Pacific partnership93, and the Union for International Cancer Control94), and, importantly, HICs within 
these regions, many of which have close relationships with neighbouring SIDS.  We have developed 
priority recommendations targeted at these groups, which are detailed in Textbox 3. These 
recommendations can and should be operationalised at both regional and global levels, and 
developed in partnerships between organisations within the global community and SIDS themselves 
(either as individual countries or as a collaborative group/ region). 
 
Concluding statement  
There are more than 50 heterogeneous SIDS globally facing major challenges in cancer control 
relating to their unique circumstances. While this paper cannot possibly capture all the complexity 
and nuance of those many nations, we hope that the work presented here, and in the other four 
papers in this series, has highlighted both the key gaps and the many opportunities to improve 
cancer outcomes in SIDS around the world.  
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Textbox 3: What can the global community do to help? 
1. International agencies or neighbouring HICs should assist SIDS in making the economic 
case for investing in cancer prevention and care - both for a domestic policy audience, and 
when applying for funding support from external sources. This might include mapping of 
needs and services, evaluation of the economic costs of cancer, costs of cancer care 
resourcing, or cost-effectiveness evaluations of specific interventions (such as cervical 
cancer prevention).    
2. Overseas Development Aid should include cancer control. Too often complex NCDs are 
excluded from directly allocated expenditures for health. ODA support for cancer control 
should be included in health system strengthening loans and grants, and should be linked to 
the phased development of national cancer control planning and operational plans for multi-
country referrals.  
3. Where possible, take steps to facilitate SIDS’ procurement of high-quality vaccines, and 
cancer technologies for surgery, pathology, imaging, radiotherapy (where appropriate), 
and systemic therapies (cancer medicines). For example, GAVI (the international vaccine 
alliance) has been instrumental in helping resource-poor countries gain access to affordable 
vaccines (including HPV vaccines), but could do more to focus on the specific needs of SIDS.  
4. Support workforce development and capacity by co-developing education and training 
programmes, partnership arrangements, tele-mentoring, and virtual clinics. Several 
effective examples of these kinds of interventions exist, for example, the Pacific Island 
Project of the Royal Australasian College of Surgeons with local Pacific universities and the 
Pacific Island Surgeons Association have collaborated to increase the number of locally 
trained surgeons.(cite papers 2 , Ekeroma et al) 
5. Provide technical assistance and research support to SIDS led programs. There is an urgent 
need to conduct health systems, economic, pathways and models of care research to inform 
policy, enhance quality of care and improve outcomes for cancer patients. This also requires 
capacity building in local data collection; investment in the IARC Caribbean and Pacific 
Cancer Registry Hubs through the Global Initiative for Cancer Registry Development (GICR) 
will significantly improve cancer surveillance and monitoring systems in SIDS.   
6. Support SIDS’ efforts to reduce importation and consumption of commodities that 
increase population cancer risk (tobacco, alcohol, unhealthy food products). In particular, 
HICs that trade with SIDS should respect these countries’ efforts to protect their populations 
from unhealthy imported products rather than challenging such measures under trade 
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agreements in order to protect their export markets, as the U.S., Australia and New Zealand 
have all done in the past.95,96  
7. Provide technical and legal support for effective health governance and cancer prevention, 
including how Ministries of Health and civil society organisations can strengthen public 
policies to reduce consumption and manage terms of engagement with commercial 
industries producing unhealthy commodities (tobacco, alcohol, and processed foods and 
beverages). 
 
 
Search strategy and selection criteria 
References were identified through searches of PubMed and grey literature with no earliest date 
specified and up until December 2018, with the search terms “Caribbean”, “Pacific”, “Small Island 
Developing States”, “Cancer”, “SIDS”, “regionalisation or regionalism”, “workforce”, “tobacco 
control”, “NCD control”, “surveillance”, “research” and “International referrals”. Grey literature from 
key international agencies was searched including from the WHO, World Bank and the UN, and 
individual country reports (for AIMS SIDS). Additional information was obtained from agendas and 
reports from key regional health leaders meetings (such as meetings of the Heads of Health, and 
Ministers of Health of the Pacific and Caribbean), and Government and non-Governmental websites 
We systematically collected specific information in cancer control activities from Ministry of Health 
officials and on-the-ground experts from the countries included in this series (see appendix p.1 for 
list of key informants). Only papers and reports published in English were reviewed.  References 
were included on the basis of originality and relevance to the broad scope of this report. 
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Abstract 
Cancer is a leading cause of death in Small Island Developing States (SIDS), and is forecast to increase 
substantially over the coming years. Governments, regional agencies, and health services of SIDS 
face daunting challenges - including small and vulnerable economies, unequal distribution of 
resources, weak or fragmented health services, small population sizes making sustainable workforce 
and service development problematic, and specialised cancer services unavailable to many. 
Deliberate action is required to prevent massive human and economic costs relating to cancer. This 
paper highlights challenges and opportunities for SIDS, and identifies ways in which the international 
community can support efforts to improve cancer control in these settings. Our recommendations 
focus on funding and investment opportunities for cancer-related health system strengthening, 
sharing of technical assistance for research, surveillance, workforce and service development, and 
supporting SIDS with policies changes to reduce consumption of commodities that increase cancer 
risk. 
Introduction 
What are Small Island Developing States?  
In 1992, the United Nations (UN) formally recognised a group of small island developing countries 
that faced ‘specific social, economic and environmental vulnerabilities’.1 These countries vary 
substantially in their development, size, cultures, languages, and history, but they also share certain 
features – including geographical isolation, fragile economies, ageing populations, and environments 
affected by global warming, making them vulnerable to natural disasters. Most have small 
populations and limited economies of scale, and are therefore heavily reliant on resources from 
larger neighbouring countries despite the high cost of transport, infrastructure, and 
communications.1 Another common feature of these countries – closely linked with these 
characteristics – is their often under-developed health systems including limited workforce resource.   
Whilst there are no specific criteria for being classed as a Small Island Developing State (SIDS), more 
than 50 countries (not all of them islands) are currently recognised as such (Table 12). SIDS are 
located across three broad geographical areas: the Pacific; the Caribbean; and the Atlantic, Indian 
Ocean, Mediterranean, and South China Seas (AIMS). They are represented by a number of regional 
organisations, including the Caribbean Community,3 the Pacific Community,4 the Indian Ocean 
Commission,5 and the Alliance of Small Island States (AOSIS)6 which acts as a regional integration 
forum to address common challenges of economic, social, and sustainable human development.6 
Some regional organisations deal specifically with health issues: for example, the Caribbean Public 
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Health Agency (CARPHA) 7 has a focus on communicable diseases, disaster management, and the 
surveillance and prevention of non-communicable diseases (NCDs), while the Pan American Health 
Organization (PAHO)8 operates as the regional office of the Americas for the World Health 
Organization (WHO), and the health agency of the Organisation of American States.  
State of cancer control in SIDS  
The unique and heterogeneous nature of SIDS is often overlooked within global, or low and middle-
income country (LMIC) cancer control agendas. Their small size is associated with capacity issues in 
key aspects of cancer prevention and control, from functioning registries to access to radiotherapy. 
This paper aims to highlight specific challenges and opportunities for SIDS, and to identify ways in 
which the international community can support governments, academic institutions, and civil society 
efforts to improve cancer control in these settings. 
Pacific and Caribbean regions 
The first four papers in this series outlined the state of cancer control in the two main SIDS regions, 
the Pacific and Caribbean. Both regions share characteristics common to (most) SIDS – that is, small, 
geographically dispersed populations with limited financial and healthcare resources. Both struggle 
with adequate human resources for health and the impacts of global warming and natural disasters, 
with seven of the fifteen countries at highest risk of such impacts (Vanuatu, Tonga, Solomon Islands, 
Papua New Guinea, Fiji, Costa Rica and Kiribati) located in one of these two regions.9 Both Pacific 
and Caribbean countries experience policy and intervention gaps along the cancer control 
continuum, although the scope and likely solutions to these problems differ. On the upside, the 
relatively small populations and strong cohesion across the two regions may offer opportunities for 
flexibility and innovation in collective approaches to cancer control.10 On the international stage, the 
SIDS have frequently formed an effective lobby  in advocating for greater attention to climate 
change and its impacts on their economies and environments.11  
There is substantial heterogeneity both within and between these two regions. The Caribbean 
contains considerably more wealth, albeit distributed very unevenly.12 Private health care plays a 
substantially bigger role in specialised cancer care, with private public partnerships representing a 
prominent approach to delivering such care (ref paper 3, Spence et al). In the Pacific, more limited 
cancer care is available on a highly centralised basis, due to very small populations and vast 
geographic distances. In the Caribbean, treatment requiring substantial capital or infrastructure 
(such as radiotherapy) is available in some countries, but frequently with challenges in maintaining 
quality, and accessible only to those able to pay. In the Pacific, specialist facilities are often absent 
altogether – meaning many treatments are available only to those who can afford to seek them in 
5 
 
neighbouring countries. Thus, both regions experience marked inequalities in access to cancer care, 
though the underlying mechanisms are somewhat different. 
Textbox 1: Role of the Commonwealth in cancer control in SIDS 
Many countries in both the Caribbean and Pacific belong to the Commonwealth – which provides a 
sense of connection and community in a shifting global landscape. Many island populations in the 
Caribbean identify more closely with the Commonwealth than with Latin America; while the Pacific 
includes eleven Commonwealth member states, all discrete island nations except Papua New 
Guinea. The Commonwealth’s networks and convening power mean it is well-placed to contribute to 
cancer control efforts in these regions. It can provide representation at international fora (such as 
the UN), high-level advocacy on issues relevant to member countries, and has a track record for 
effecting change in areas of common concern such as climate change and antimicrobial resistance.  
Consistent with the UN’s third Sustainable Development Goal (SDG) and Political Declaration on 
NCDs, the Commonwealth has recognised NCDs as “a human development challenge which needs to 
be tackled urgently”13 and has expressed commitment to raising awareness, mobilizing resources, 
and ensuring accessibility to the necessary prevention and treatment services.14-16 In relation to 
cancer, the Commonwealth has led on some relevant initiatives. For example, the ‘Cervical Cancer in 
the Commonwealth: Collective Action’ programme has analysed the burden of cervical cancer in 
LMICs of the Commonwealth.17  
Much more needs to be done, however, and this series of papers should catalyse further 
Commonwealth action on cancer. While still lacking a comprehensive cancer strategy, new initiatives 
such as the Commonwealth Innovation Hub have the potential to enhance and co-ordinate cancer 
control efforts among member states.18 There have been calls to establish a Commonwealth Cancer 
Fund to “build up capacity in cancer control in the smaller and less economically advantaged 
Member States through skills training and multilateral aid.”19 In relation to the Caribbean and Pacific 
Islands, there is interest in Commonwealth support for Human Papilloma Virus (HPV) vaccination 
and cervical screening in its member states, and for improvements in the early detection, diagnosis, 
and treatment of childhood cancers.20  
 
AIMS SIDS 
Outside the Pacific and Caribbean regions, there are other UN-recognised SIDS collectively referred 
to as AIMS SIDS (table 221-25). In addition, there are other island countries and territories not 
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explicitly mentioned in this paper which share similar experiences and challenges, and which 
similarly need support to develop more effective cancer control systems.  
There is marked variation between the AIMS SIDS (table 2). At one end of the spectrum, Singapore 
and Bahrain are high-income countries (HICs) with national population-based cancer registries, 
operational cancer and NCD plans, and comprehensive cancer services providing specialised surgery, 
chemotherapy, radiotherapy, and palliative care. Conversely, advances in cancer surveillance, 
screening and prevention, diagnosis, and care have been limited in almost all other AIMS SIDS. For 
instance, the Comoros and Guinea-Bissau are among the poorest countries in the world and struggle 
to meet their populations’ basic needs: sanitation, nutrition, transportation, and basic healthcare. 
Life expectancy remains low, and fragile health systems are burdened by multiple competing 
priorities including infectious diseases. Long periods of civil unrest in Guinea-Bissau have resulted in 
debilitated health systems, significant workforce shortages, and delayed progress in health 
infrastructure development. The double burden of lifestyle and infection related cancers is evident 
in many of these SIDS, with GLOBOCAN 2018 estimates showing the most common cancers are 
breast, cervical, and colorectum in women, and colorectum, prostate, liver, and lung in men (table 
326).  
Outside of Bahrain and Singapore, cancer surveillance and prevention programmes are very limited. 
Mauritius and Seychelles are the only other AIMS countries (besides Bahrain and Singapore) to have 
population-based cancer registries, although pockets of cancer registration activity occur elsewhere 
(for example, Cape Verde has a hospital-based cancer registry). Despite the high burden of 
preventable cancers, none of these countries have established national screening programmes for 
cervical or breast cancers, and only two (Mauritius and Cape Verde) have operational standalone 
cancer plans in place. More positively, uptake of hepatitis B immunisation has been successful (>90% 
coverage) in most of these SIDS. A growing number of SIDS are incorporating Human Papilloma Virus 
(HPV) vaccination into their national schedules, with the Maldives recently approving HPV for roll-
out to 9-15 year old girls.27 As with other SIDS, many cancer prevention and educational campaigns 
in these countries are spearheaded by non-governmental organisations (NGOs) or patient groups.28  
Diagnostic and treatment services are variable in all AIMS SIDS besides Bahrain and Singapore. The 
availability of histology and cytopathology services is very limited, and none have positron emission 
tomography (PET) scan capability. Chemotherapy is available in four countries, and Mauritius is the 
only AIMS SIDS (besides Bahrain and Singapore) with radiotherapy capabilities. Like other small 
islands globally, some AIMS SIDS have established pathways for accessing diagnostic and treatment 
services off-island by sending selected specimens or patients to neighbouring countries and/or 
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receiving visiting specialist services.28 For instance, Cape Verdeans may be transferred to Portugal for 
radiotherapy and other oncological treatment not available in-country; patients from the Seychelles 
may seek comprehensive care in Sri Lanka, Reunion, or India; and Mauritius has an overseas 
treatment scheme for brain tumours.  
Like the Pacific and Caribbean SIDS, innovations in cancer control and care are emerging in these 
SIDS. For example, the Comoros has partnered with the Felix Guyon University Hospital, Reunion, to 
provide a route for cancer diagnosis by sending tissue samples offshore, and with Mauritius and 
Madagascar to improve chemotherapy delivery on Comoros. Oncologists from the Portuguese-
speaking SIDS (Cape Verde, São Tomé and Príncipe, and Guinea-Bissau) are collaborating to advance 
cancer control efforts via strategies such as improving access to cancer care, increasing cervical 
cancer screening and HPV vaccination, and developing educational, training and research pathways 
through their connection as PALOP (Países Africanos de Língua Oficial Portuguesa) countries.28  
Textbox 2: SIDS, the sustainable development goals and universal health coverage 
The sustainable development goals (SDGs) include target 3.4, to reduce by a third premature 
mortality from NCDs through prevention and treatment. However, the potential role of NCD control 
in achieving SDGs (or not) extends well beyond this specific target.29 The special case of SIDS in 
achieving and prioritising sustainable development was detailed in the SIDS accelerated modalities 
of action (SAMOA) pathway, which was developed at the third International Conference of SIDS in 
2013, and resulted in a resolution adopted by the general Assembly of the U.N. in 2014.30 The 
SAMOA pathway acknowledges the significance of health as foundational across SDGs, identifies the 
critical importance of international cooperation and partnerships in achieving them, and the central 
role of multisectoral strategies for both preventing and managing NCDs. This includes the 
strengthening of health systems and acceleration of universal health coverage implementation. SIDS 
vary substantially in terms of the extent to which they need to  address the three inter-related 
elements of coverage as defined by the WHO31; ensuring financial protection by reducing reliance on 
out-of-pocket payments for patients, expanding the services covered ensuring that those selected 
are high priority, cost-effective and high quality services, and increasing the population covered. For 
example, in several Caribbean countries, out-of-pocket payments of cancer care remain high, while 
in most Pacific SIDS, a key issue is the relatively narrow scope of cancer treatment services available. 
Responding to these challenges, and the burden of cancer generally, requires integrated and 
coordinated policies and strategies within SIDS, with international partnerships and support to 
prevent and treat cancer. Progress in cancer control is absolutely integral to accelerating progress 
towards achieving SDGs within the challenging context facing SIDS.  
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Common threads leading to recommendations 
Many reports have summarised evidence on cancer control requirements within LMICs and 
developed recommendations for strengthening existing systems.32-40 These have relevance for SIDS, 
although the unique circumstances of remote island states create distinctive challenges for cancer 
control. While acknowledging the diversity of this heterogeneous group, we highlight below the 
common themes in SIDS’ experience of addressing the burden of cancer in their populations and 
implications for policy. 
Monetary and Fiscal Policy for Cancer Control in SIDS 
The economic case for investing in cancer control - from specific modalities such as radiotherapy and 
surgery through to population-based measures such as women’s health initiatives, HPV vaccination 
and bowel cancer screening - is equally applicable to SIDS.34,36,37 Good outcomes in cancer control 
are also highly sensitive to equity-centred fiscal policy, requiring significant public health 
expenditure (about 5-6% of GDP and at least $100USD per capita) and effective governance.41 
Where private investment and provision for cancer is present, it should be a minority partner that is 
well integrated into public care. This runs counter to the World Bank’s historic approach to SIDS, 
which focuses on private sector-led growth in health and cancer care that necessarily requires 
stable, progressive economies. Yet SIDS have some of the most vulnerable economies in the world, 
facing serious constraints due to demographic and geographic characteristics. It is clear that 
investment in public health care is critical to maintain economic growth, even if this comes with 
larger budget deficits.42 Cancer is a major cause of lost productivity due to premature mortality and 
morbidity, and effective public investment in cancer prevention and early diagnosis (including 
tobacco control, vaccination, and screening) will reduce the economic burden of cancer in 
transitioning economies.43 Unfortunately, some SIDS are currently pursuing unaffordable programs 
focused on costly treatment of conditions affecting a small proportion of the population.44 The 
failure to invest and tackle the causes of cancer – such as tobacco consumption - seriously 
undermines the economic sustainability of many SIDS (see section below on NCD prevention).  
Growth in population-level drivers of cancer (such as tobacco and obesity) are expanding the burden 
of cancer in SIDS beyond what can be addressed via current fiscal policy. Given infection-related 
cancers are still high, the emergence of a “double disease burden” creates substantial economic 
challenges in supplying even a basic package of cancer care, which may be beyond what individual 
SIDS can achieve. Joint country models need to be examined, where geographically co-located SIDS 
create a single ‘system’ (discussed further below). It may be feasible and cost effective to provide 
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only basic community services in those SIDS with good access to specialist facilities in neighbouring 
HICs.45 There is a need for more empirical evidence on the cost-effectiveness of such models and 
pathways. Ad hoc support though official development assistance (ODA) funding is not a long term 
solution;46 rather, major ODA programs need to be created that specifically address cancer control in 
SIDS via public health and prevention initiatives. More widely, new tariffs and excise duties on 
unhealthy commodities need to be built into bilateral trade agreements in order to reduce the 
drivers of cancer and generate revenue for prevention and control activities, while still retaining 
SIDS’ access to global markets which are crucial to sustainable economic growth.47  
Regionalisation of cancer planning and services 
A common practice among island nations is regional collaboration with external partners to facilitate 
the management of health programmes, including (in recent years) cancer control programmes. 
Such programmes typically involve an interweaving of regionalization (in which an external agency 
works in collaboration with a particular geographical region) and regionalism (in which individual 
countries within a geographical region come together for a common specific purpose, supported by 
bodies that express their collective identity and shape collective action). 
The WHO often works in collaboration with a particular geographical ‘region’ in management of 
specific health care needs. In the Pacific, for example, this regionalisation has allowed prompt and 
affordable access by smaller nations to technical expertise for programme development. The Cancer 
Council of the Pacific Islands (CCPI), which operates in U.S.-affiliated Pacific islands (USAPIs), 
provides a well-established example of how locally-controlled regionalism can be initiated, with the 
CCPI using the University of Hawai’i as a gateway to funding and support, leading to a regionally-
recognized cancer control plan and registry.48,49 A further example of regionalisation is provided by 
the Pacific Regional Cancer Control Partnership (PRCP), which includes international partner 
agencies.49 Managing cancer control in SIDS at a regional level means that collaborating SIDS can 
share resources and gain greater leverage for funding requests and global advocacy.  
A regionalisation strategy for cancer prevention and control may be an effective way forward for 
SIDS in other regions. Regional efforts are most likely to be effective where they link countries that 
share a common language, historical and/or political affiliations in addressing a common need or 
goal such as national comprehensive cancer planning, or the development of regulation of medicines 
and health technologies.50,51 Opportunities for such linkages may be found in existing government-
led initiatives (e.g. the Caribbean Cooperation in Health and the Ministers of Health Caucuses of 
both the Pacific and Caribbean regions), in national and international cancer societies, in regional 
and local networks of NGOs (e.g. the Caribbean Cooperation in Health), in academia, or via 
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international organisations such as the International Agency for Research on Cancer (IARC) which 
has established cancer registry hubs in many regions. 
The motivation for specific SIDS to be involved in regionalization or regionalism efforts will vary, 
depending on individual country resources, needs, and geopolitical support. High level regionalism 
requires support from health leaders in the relevant countries in order to identify the preferences, 
scope and nature of the collaborations.  In order for such approaches to be effective, there needs to 
be sufficient political will (both across and within partner countries) to sustain collective action and 
outcome; mutually agreed institutional ‘housing’ and governance structures; and ongoing review 
processes. Equally important is that leadership and decision-making occur collaboratively, and 
reflect the needs and priorities of the constituent countries.   Regional agencies, academic 
organisations, and non-Governmental Organisations are critical to provide resource for planning and 
working to deliver key actions according to agreed regional approaches.  
Implementation policy that supports NCD control more generally  
SIDS face particular challenges in developing coherent and effective approaches for cancer 
prevention. Key drivers of the growing cancer burden in these states include their dependence on 
and vulnerability to imported goods – some of which are health-promoting, but many of which are 
health-damaging.52,53 In line with a broader development agenda, many SIDS have been encouraged 
to follow a programme of trade liberalisation as a means of attracting foreign investment and 
reducing the cost of imported goods.52 The removal of trade barriers has been associated with 
increased consumption of tobacco, alcohol, and highly processed food and drinks, which collectively 
account for around 30% all cancers.54,55 
 
Cancer prevention thus requires measures to reduce population consumption of unhealthy 
commodities, with the most effective strategies involving taxation, tariffs, and restrictions on 
marketing.33 While SIDS experience particular challenges in balancing health and trade goals, there 
are some promising examples of successful efforts to protect island populations from unhealthy 
commodities.56 The Cook Islands, Palau, and Tonga have all introduced tobacco taxes close to the 
WHO target (70% of the sale price)57; several Pacific and Caribbean countries have imposed 
significant taxes on alcohol and sweetened beverages;58-60 and some Pacific countries have banned 
importation of specific unhealthy items such Tokelau’s ban on the importation of sweetened fizzy 
drinks.52 While there is ongoing work across the Caribbean to address these issues, there is scope to 
do more, however, particularly in relation to tobacco control in the Caribbean,61 where several SIDS 
lack effective advertising bans and have tax levels below 25%.57,62 Raising taxes on tobacco, alcohol, 
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and sugar-sweetened beverages has the potential to increase government revenue while also 
reducing the burden of NCDs.33 
 
Developing cancer treatment services in SIDS  
 
Workforce 
Efforts to strengthen their health workforces will be key to enhancing cancer control within SIDS. As 
with many LMICs, SIDS struggle with limited workforce training, retention, professional support, and 
development opportunities, exacerbated by a lack of infractructure and equipment; movement of 
resources from public to private settings; and migration of specialised healthcare workers to HICs. In 
addition, the small population size of many SIDS limits the feasibility of specialised services, including 
cancer treatment centres, with models from HICs or even larger LMICs not applicable in these 
settings.63 For example, a recent analysis noted than ocology stafffing is insufficient to meet the 
current demands of the poluation.64 While the need for workforce development is recognised within 
the SDGs (target 3c), 65 SIDS are competing with other countries in a context of marked scarcity, with 
the global shortage of health workers estimated to reach 15 million by 2030.66 
 
The challenges facing SIDS in developing a cancer workforce are daunting. Given their small and 
dispersed populations, highly specialised services are neither feasible nor affordable. For many SIDS, 
treating patients offshore is the only option – but health-related travel is expensive and complex and 
results in poor continuity of care, high out-of-pocket costs for patients and their families, and limited 
incentive to improve local services.67 
 
Despite these challenges, there are significant opportunities for strengthening the cancer control 
workforce within SIDS. Health workforce development is a priority in both the Pacific and Caribbean 
regions, with efforts underway to improve workforce planning, education and training, as well as its 
regulation and monitoring.68,69 Regional or subregional approaches can enhance the efficiency and 
the effectiveness of health workforce planning, and offer opportunities to share successful 
approaches. In the Pacific, for example, health workforce development has been a major agenda 
item in recent meetings of the Pacific Health Ministers;70 and there are a number of collaborative 
groups and programmes that work to enhance training and continuing professional development, 
including the Pacific Regional Clinical Services and Workforce Improvement Program.70 Significant 
challenges persist, however, including a lack of specific attention to cancer prevention and 
treatment in workforce development.70 Similarly, in the Caribbean, several adhoc efforts for training 
12 
 
and building cancer workforce capacity have taken place, however a systematic process for cancer 
control workforce planning, development, and continuing education is still needed in the region.   
 
Role of traditional healers 
In most SIDS, traditional healers play an important role, but there is almost no research on either 
their impact on health or their potential to provide links between traditional and conventional 
medicine. Many people in SIDS will visit their traditional healer before seeking conventional medical 
care, and will continue to do so during treatments, and at the end of life. Traditional healers work 
with patients and families within their own communities. They use concepts and language that are 
familiar and congruent with understandings of health and disease within those communities.  
Engaging with these healers, and encouraging a complementary approach with conventional 
medicine, is likely to pay dividends. For example, more timely diagnosis and access to treatment may 
be achieved by training healers to recognise common cancer symptoms and refer patients to 
conventional services; while the involvement of traditional healers in conventional cancer care may 
improve its accessibility and provide patients with ongoing spiritual and mental support. Such 
innovative approaches would require identifying traditional healers who are prepared to work in 
partnership with conventional medicine, ongoing relationship building, consideration of the need for 
structural changes in the clinical setting to provide space for traditional healers, consideration of 
training needs of those healers, and attitudinal shifts for clinicians.71 
 
Ensuring a reliable and affordable supply chain 
A robust supply chain of essential medicines and supplies is essential to deliver effective and timely 
cancer diagnosis and treatment. Individually SIDS have little purchasing power, and little prospect 
for economies of scale. Centralised approaches to procurement and supply have been found to 
generally both reduce costs and improve supply including across countries.51,72 One of the most 
successful examples is the Organisation of Eastern Caribbean States Pharmaceutical Procurement 
scheme (OECS-PPS) which was established in 1986.73 The OECS-PPS operates as a monopsony 
purchaser of pharmaceuticals and medical supplies to nine small island countries. This approach has 
resulted in increased bargaining power and improved economies of scale, resulting in substantial 
reductions in drug prices, as well as improved supply chain and quality assurance processes, 
reductions in operational costs and better-informed selection and standardisation of 
pharmaceuticals.74 The key success factors have previously been described in detail.73 PAHO’s 
Strategic Fund for Essential Medicines also offers a pooled procurement mechanism for medication 
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for participating countries in the Americas, including the Caribbean, resulting in improved pricing 
and purchasing, although it remains underutilised for cancer medications.75 
 
Innovative approaches to delivering cancer care for SIDS 
Innovative approaches to delivering cancer care are necessary in the context of many SIDS, where 
highly specialised models transplanted from HICs are unlikely to be useful. There is increasing 
recognition of the important role of primary care in cancer prevention, diagnosis, treatment, 
survivorship, and end of life care.39 Arguably, this is particularly critical in the context of SIDS where 
secondary care services may be limited or even absent. Where it is available, specialised cancer care 
is typically limited to regional centres, and in many cases patients will have to leave the region 
altogether to access such care. This highlights the importance of enhancing what cancer care can be 
provided within specific islands. Nurses and allied health professionals are a valuable resource, 
potentially providing a range of cancer-related care – including prevention activites (such as smoking 
cessation advice), screening, treatment, palliative and survivorship care.76,77  Supportive and 
palliative oncological care is provided by generalist medical practitioners in some SIDS; this could 
potentially be extended with input from colleagues in HICs. Such partnership arrangements exist for 
paediatric cancer in both the Pacific and Caribbean regions, and have resulted in subsantially 
improved outcomes for affected children (ref papers 2, Ekeroma et al and 4, Spence et al). These 
collaborations typically involve country-specific policies and procedures for communication and 
referral, as well as regular virtual and face-to-face meetings between clinicians based in SIDS with 
those based in HICs. A number of factors must be in place for such models to be effective and 
sustainable, including a commitment from the government and relevant healthcare workers that 
providing basic oncological services is a priority; training and professional support opportunities; and 
access to relevant infrastructure, policies and procedures, and equipment. 
 
Online professional development, consultation, and mentoring programmes offer particular 
potential for SIDS, and are already supporting care in some contexts. For example, the Pacific Open 
Learning Health Net (POLHN) was established by the WHO and Pacific Ministers of Health in 2003, 
and provides accredited, freely accessible learning opportunities for health workers in the region on 
a broad range of topics.78 Currently, the majority of these are not cancer-related, but such a 
platform would be ideally placed to increase training opportunities for cancer care workers.  
 
Other technological solutions to support local healthcare workers include the use of telemedicine 
and point of care technologies. These collectively have great potential for improving cancer 
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detection, diagnosis and treatment, particularly in settings with limited infrastructure, as is the case 
in many SIDS.79  Telemedicine can particularly support local clinicians  with pathological and 
radiological diagnosis. 40  Point of care technologies have a range of uses, including HPV screen and 
treat programmes that have been positively evaluated in SIDS settings.79-81 Tele-mentoring 
programmes such as the Extension for Community Healthcare Outcomes (ECHO) program support 
local clinicians to provide care of complex diseases with support and mentoring from specialists. 82 
The ECHO program runs regular virtual ‘clinics’ held using commonly available videoconferencing 
technology, where local clinicians can present and discuss cases, and specialists, based in central 
hubs, can provide expert knowledge and experience. ECHO is increasingly being used across the 
cancer control continuum in LMICs settings - including in the Caribbean - to support comprehensive 
cancer plan development.83 This approach could be expanded improve access to specialist cancer 
care in other SIDS. 
 
Both telemedicine and tele-mentoring approaches require consistent, reliable, and affordable 
internet access, which may be problematic in some SIDS. Other potential barriers include high set-up 
costs, particularly for telepathology (which requires high-quality imaging), regulatory and legal 
requirements, and quality assurance processes for experts (such as pathologists) based in other 
countries.40 However, the clear advantage of telemedicine is that health services in small countries 
may be able to access expertise in contexts where it is not feasible for them to maintain highly 
specialised services in-country. 
 
International referrals  
For many SIDS, it is not feasible to deliver comprehensive cancer treatment in-country – meaning 
patients must sometimes travel internationally for treatment. Travelling to receive treatment out-of-
country can be complex and expensive, particularly in the context of time-sensitive care. Even where 
treatment costs are covered by Government, costs to patients for travel and accommodation can be 
catastrophic, or entirely out-of-reach for many patients. In addition, in order to ensure timely 
treatment, processes to facilitate treatment offshore must be efficient and streamlined. Given 
scarce resources, and high demand, this is not always the case. There is very little empirical research 
on the impact and costs of international referrals, nor on optimal models of such referrals. Critical 
questions remain unanswered on nearly every aspect of these referrals including the psychosocial, 
economic, and health impacts of international referrals on patients and their families, the impact of 
costs of these referrals on the referring country including their effect on the development of local 
services, identification of factors that make such referrals more or less successful, and the potential 
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role of the international community in assisting with funding or coordinating such referrals. Research 
in this area is urgently required. 
Building surveillance and research infrastructure  
Underpinning all the work required to strengthen cancer care within SIDS is the necessity for data 
systems to support cancer surveillance and inform locally-relevant priorities and policies. Evidently 
effective surveillance programmes including risk factor surveys, vital registration systems, and 
population-based cancer registries (PBCR), as well as clinical information systems are all esential to 
plan and evaluate interventions tailored to the local scale and profile of cancer. Cancer registration 
has a long history in SIDS, but has been historically challenged by limited health care infrastructure, 
including pathologist services. As a means to improve data quality and PBCR coverage in the 
Caribbean and Pacific Island regions, the IARC, with several partner organisations, have developed 
IARC Regional Hubs, as part of the Global Initiative for Cancer Registry Development 
(http://gicr.iarc.fr). The Regional Hubs provide the necessary technical guidance, training, advocacy, 
and research capacity-building to ensure the sustainable development of high-quality PBCR in these 
regions. A sustainable expansion of high-quality registries in the SIDS is thus feasible and underway, 
but given small population sizes in many states, regional approaches equally apply to surveillance, 
including PBCR. As with other programmes of local data collection, funding remains problematic for 
this initiative, despite the relatively small amounts required.   
 
Local evidence to inform policy design and programme delivery in cancer control and prevention is 
badly needed in the SIDS. While there are many examples of productive partnerships between HICs 
and SIDS, research systems are often under-developed or non-existent in many SIDS.84-86 The 
ongoing building of research capacity and infrastructure is essential for progressing SIDS’ cancer 
control efforts as the health and cost burdens grow. This will be facilitated by continuing 
development of genuine collaborations between SIDS and HICs that address local research priorities, 
strengthen research infrastructure, and create impact by interpreting and implementing research 
findings in a way that is appropriate to local context.87  
 
Start with the things that are likely to be easier, cheaper and quicker to implement with high impact  
In seeking to manage cancer, SIDS face difficulties common to many LMICs while also experiencing 
some unique challenges. Cancer control in these settings is often seen as prohibitively expensive, 
and a lack of strategic prioritisation leads to missed opportunities for its inclusion in broader health 
systems strengthening agendas.88 Yet much can be done to reduce suffering and premature death 
from cancer, even in resource-constrained settings.  
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The WHO recommends a stepwise approach to building a national cancer programme.89 Alongside 
this, it encourages the prioritisation of effective tobacco control policies in order to reduce the most 
significant risk factor for cancer. As noted above, taxes on tobacco can also provide much-needed 
revenue to support health systems development.  
Interventions based in primary and community settings offer particular promise in resource-poor 
settings. Such programmes can be effective even in the absence of specialist services or 
infrastructure, and offer alignment with broader development and universal health care goals. 
Palliative care is explicitly recognised under the human right to health.38 In LMICs, and even in SIDS 
classified as HICs, palliative care is an often neglected aspect of cancer care. This is particularly 
significant given that these countries are dealing with a high percentage of cancer patients with 
advanced disease for whom palliative care and pain relief are often the only option. Palliative care 
can be substantially enhanced via existing primary and community-based services. While many 
aspects of cancer care require costly and/or sophisticated treatment modalities, palliative care can 
be strengthened at relatively low cost by improving access, understanding, and coordination of care 
within existing systems.38 Key priorities include efforts to increase the accessibility of essential 
medicines including immediate release and injectable morphine, simple equipment, and 
competency based human resources.38 The essential package (of palliative care and pain relief 
health services) has been shown to be inexpensive and is applicable in countries at all stages of 
palliative care development.38 Regional organisations such as the Caribbean Palliative Care 
Association play an important role in raising awareness and coordinating provision of palliative care, 
which is often misunderstood and/or neglected in existing health systems.90  
 
Prevention of cervical cancer – a leading cause of cancer death in many SIDS – offers significant 
potential gains. HPV vaccination and cervical screening are cost-effective interventions recently 
highlighted as priorities by the Director General of WHO.91 The international community can help 
SIDS strengthen their cervical cancer prevention efforts by supporting regional purchases of HPV 
vaccines and assisting countries in designing and implementing screening programmes tailored to 
their local context. For example, Papua New Guinea has introduced point-of-care screening using 
HPV-DNA testing; this offers a promising approach in SIDS countries where cytology is not available 
and approaches based on VIA (visualisation of the cervix after acetic acid) have had poor results.81,92   
The role of the global cancer control community 
 
17 
 
Global efforts in cancer control have tended to focus on issues facing LMICs but not the particular 
vulnerabilities of SIDS. Smaller populations with inherent capacity issues, geographic isolation and 
environments increasingly affected by the consequences of global warning result in unique 
challenges. While, the sovereignty of states is paramount in the development of health policy, the 
global community has an important role in facilitating SIDS’ own efforts to strengthen their cancer 
prevention and control systems. Key members of the global community include international 
organisations (such as WHO and its regional offices in the Americans and the Western Pacific), global 
alliances and networks (such as the Commonwealth, IARC, the European Union-African Caribbean 
Pacific partnership93, and the Union for International Cancer Control94), and, importantly, HICs within 
these regions, many of which have close relationships with neighbouring SIDS.  We have developed 
priority recommendations targeted at these groups, which are detailed in Textbox 32. These 
recommendations can and should be operationalised at both regional and global levels, and 
developed in partnerships between organisations within the global community and SIDS themselves 
(either as individual countries or as a collaborative group/ region). 
 
Concluding statement  
There are more than 50 heterogeneous SIDS globally facing major challenges in cancer control 
relating to their unique circumstances. While this paper cannot possibly capture all the complexity 
and nuance of those many nations, we hope that the work presented here, and in the other four 
papers in this series, has highlighted both the key gaps and the many opportunities to improve 
cancer outcomes in SIDS around the world.  
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Textbox 32: What can the global community do to help? 
1. International agencies or neighbouring HICs should assist SIDS in making the economic 
case for investing in cancer prevention and care - both for a domestic policy audience, and 
when applying for funding support from external sources. This might include mapping of 
needs and services, evaluation of the economic costs of cancer, costs of cancer care 
resourcing, or cost-effectiveness evaluations of specific interventions (such as cervical 
cancer prevention).    
2. Overseas Development Aid should include cancer control. Too often complex NCDs are 
excluded from directly allocated expenditures for health. ODA support for cancer control 
should be included in health system strengthening loans and grants, and should be linked to 
the phased development of national cancer control planning and operational plans for multi-
country referrals.  
3. Where possible, take steps to facilitate SIDS’ procurement of high-quality vaccines, and 
cancer technologies for surgery, pathology, imaging, radiotherapy (where appropriate), 
and systemic therapies (cancer medicines). For example, GAVI (the international vaccine 
alliance) has been instrumental in helping resource-poor countries gain access to affordable 
vaccines (including HPV vaccines), but could do more to focus on the specific needs of SIDS.  
4. Support workforce development and capacity by co-developing education and training 
programmes, partnership arrangements, tele-mentoring, and virtual clinics. Several 
effective examples of these kinds of interventions exist, for example, the Pacific Island 
Project of the Royal Australasian College of Surgeons with local Pacific universities and the 
Pacific Island Surgeons Association have collaborated to increase the number of locally 
trained surgeons.(cite papers 2 , Ekeroma et al) 
5. Provide technical assistance and research support to SIDS led programs. There is an urgent 
need to conduct health systems, economic, pathways and models of care research to inform 
policy, enhance quality of care and improve outcomes for cancer patients. This also requires 
capacity building in local data collection; investment in the IARC Caribbean and Pacific 
Cancer Registry Hubs through the Global Initiative for Cancer Registry Development (GICR) 
will significantly improve cancer surveillance and monitoring systems in SIDS.   
6. Support SIDS’ efforts to reduce importation and consumption of commodities that 
increase population cancer risk (tobacco, alcohol, unhealthy food products). In particular, 
HICs that trade with SIDS should respect these countries’ efforts to protect their populations 
from unhealthy imported products rather than challenging such measures under trade 
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agreements in order to protect their export markets, as the U.S., Australia and New Zealand 
have all done in the past.95,96  
7. Provide technical and legal support for effective health governance and cancer prevention, 
including how Ministries of Health and civil society organisations can strengthen public 
policies to reduce consumption and manage terms of engagement with commercial 
industries producing unhealthy commodities (tobacco, alcohol, and processed foods and 
beverages). 
 
 
Search strategy and selection criteria 
References were identified through searches of PubMed and grey literature with no earliest date 
specified and up until December 2018, with the search terms “Caribbean”, “Pacific”, “Small Island 
Developing States”, “Cancer”, “SIDS”, “regionalisation or regionalism”, “workforce”, “tobacco 
control”, “NCD control”, “surveillance”, “research” and “International referrals”. Grey literature from 
key international agencies was searched including from the WHO, World Bank and the UN, and 
individual country reports (for AIMS SIDS). Additional information was obtained from agendas and 
reports from key regional health leaders meetings (such as meetings of the Heads of Health, and 
Ministers of Health of the Pacific and Caribbean), and Government and non-Governmental websites 
We systematically collected specific information in cancer control activities from Ministry of Health 
officials and on-the-ground experts from the countries included in this series (see appendix p.1 for 
list of key informants)., Only papers and reports published in English were reviewed.  References 
were included on the basis of originality and relevance to the broad scope of this report. 
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Figure 1. Map of the UN SIDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure
Table 1: Small Island Developing States2 
Caribbean Pacific AIMS (Africa, Indian Ocean, 
Mediterranean and South 
China Seas) 
Anguilla American Samoa Bahrain 
Antigua and Barbuda Cook Islands Cape Verde 
Aruba Federated States of 
Micronesia 
Comoros 
Bahamas Fiji Guinea-Bissau 
Barbados French Polynesia Maldives 
Belize Guam Mauritius 
Bermuda Kiribati São Tomé and Príncipe 
Bonaire, Sint Eustatius and 
Saba (BES) 
Marshall Islands Seychelles 
British Virgin Islands Nauru Singapore 
Cayman Islands New Caledonia  
Curaçao Niue  
Cuba Northern Mariana Islands  
Dominica Palau  
Dominican Republic  Papua New Guinea  
Grenada Samoa  
Guadeloupe Solomon Islands  
Guyana Timor-Leste*  
Haiti Tonga  
Jamaica Tuvalu  
Martinique Vanuatu  
Puerto Rico   
Saint Kitts and Nevis   
Saint Lucia   
Saint Vincent and the 
Grenadines 
  
Suriname   
Trinidad and Tobago   
Turks and Caicos Islands   
US Virgin Islands   
* In this series Timor-Leste is considered to be an AIMS SIDS (rather than Pacific) due to their political and social ties with 
the South-East Asian region 
 
Table
Table 2. Characteristics of AIMS SIDS (including Timor-Leste)21-25  
  Bahrain Cabo Verde Comoros Guinea-Bissau Maldives Mauritius 
São Tomé 
and Príncipe 
Seychelles Singapore Timor-Leste 
Estimated 
population (2017) 
1,492,584 546,388 813,912 1,861,283 436,330 1,264,613 204,327 95,843 5,612,253 1,296,311 
Income 
classification 
High Lower middle Lower middle Low Upper middle Upper middle Lower middle High High Lower middle 
GDP per capita 
(current US$, 
2017) 
23,655 3,244 1,312 724 11,151 10,490 1,921 15,629 57,714 2,279 
Health 
expenditure as % 
GDP (2015) 
5·16 4·8 8·0 6·9 11·5 5·5 9·8 3·4 4·3 3·1 
Life expectancy at 
birth (years), total 
79·1 73·2 63·9 59·8 78·4 74·8 68·7 73·3 82·9 68·6 
Health staff per 
10,000 population 
9·3 doctors       
24·9 nurses 
7·7 doctors          
10 nurses 
1·7 doctors             
7 nurses 
0·6 doctors         
6·9 nurses 
10·4 doctors      
57·2 nurses 
20·2 doctors      
32·8 nurses 
3·2 doctors 
9·5 doctors        
44·9 nurses 
23·1 doctors      
58·3 nurses 
6·7 doctors        
13·6 nurses  
Cancer 
registration 
National high 
quality PBCR 
Registration 
activity 
No data No data No data PBCR No data PBCR 
National high 
quality PBCR 
No data 
National cancer 
plan (year) 
Yes (2010-2020) Yes (2015) No No No Yes (2015-2019) No Yes Yes No 
Current NCD plan Yes Yes Yes No Yes No No Yes No Yes 
HBV vaccination 
coverage (BD, B3, 
%) 
98, 98 96, 96 91 (B3 only) 79 (B3 only) 99, 99 96 (B3 only) 95,93 97 (B3 only) 91, 96 62,92 
HPV vaccination 
on national 
schedule  
No No No No Yes Yes Yes Yes Yes No 
Organised 
national screening 
programme 
available 
Breast No No No No No No No 
Cervical, Breast, 
Colorectal  
No 
Radiology services 
Xray, USS, 
MMG, CT, MRI, 
PET  
Xray, USS, MMG Xray, USS 
Xray, USS, MMG, 
CT 
Xray, USS, 
MMG, CT, MRI  
Xray, USS, 
MMG, CT, MRI  
Xray, USS, CT 
Xray, USS, 
MMG, CT, MRI  
Xray, USS, 
MMG, CT, MRI, 
PET  
Xray, USS, CT 
Table
Pathology services 
Cytology, 
histology, IHC 
n/a n/a n/a 
Cytology, 
histology 
Cytology, 
histology, IHC 
n/a 
Cytology, 
histology, IHC 
Cytology, 
histology, IHC 
n/a 
Publicly available 
cancer treatment 
services 
Surgery 
Chemotherapy 
Radiotherapy  
Surgery 
Chemotherapy  
Surgery Surgery 
Surgery 
Chemotherapy  
Surgery 
Chemotherapy 
Radiotherapy  
Surgery 
Surgery 
Chemotherapy  
Surgery 
Chemotherapy 
Radiotherapy  
Surgery 
Oral morphine 
available in public 
health sector 
Yes No No No No Yes No Yes Yes No 
GDP: Gross domestic product 
PRCR: Population-based cancer registry 
NCD: Non-communicable disease 
HBV: Hepatitis B Virus (BD: birth dose, B3: infant doses) 
USS: Ultrasound 
MMG: Mammography  
CT: Computerised tomography 
MRI: Magnetic resonance imaging 
PET: Positron emission tomography 
IHC: Immunohistochemistry 
Table 3. Top 5 most commonly diagnosed cancers in men and women for the AIMS SIDS (including Timor-Leste, excluding Seychelles), GLOBOCAN 201826  
 
 
1 2 3 4 5 1 2 3 4 5
Bahrain Colorectum Lung Prostate Bladder NHL Breast Colorectum Ovary Uterine Thyroid
Cape Verde Prostate Stomach Oesophagus Lung Liver Cervix Breast Stomach Colorectum Liver
Comoros Prostate Oesophagus Liver NHL Colorectal Cervix Breast Oesophagus NHL Liver
Guinea-Bissau Liver Prostate Stomach Colorectum NHL Cervix Breast Liver Colorectum Stomach
Maldives Lung Colorectum Nasopharynx Liver Prostate Breast Cervix Ovary Thyroid Colorectum
Mauritius Prostate Lung Colorectum Stomach Bladder Breast Colorectum Cervix Uterine Ovary
Sao Tome and Principe Prostate Lung Stomach Liver Bladder Cervix Breast Ovary Lung Stomach
Singapore Prostate Lung Colorectum Liver Kidney Breast Colorectum Lung Uterine Ovary
Timor-Leste Lung Colorectum Nasopharynx Liver Prostate Breast Cervix Colorectum Lung Ovary
Top 5 -male Top 5 - female
Table
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